Cargando…
Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma
Talimogene laherparepvec (T-VEC) is an intralesional oncolytic virotherapy for patients with irresectable stage III–IVM1a cutaneous melanoma. Although this treatment is considered to mainly act through T cell-mediated mechanisms, prominent numbers of plasma cells after T-VEC treatment have been desc...
Autores principales: | Mulder, Evalyn E.A.P., Damman, Jeffrey, Verver, Daniëlle, van der Veldt, Astrid A.M., Tas, Sam, Khemai-Mehraban, Tamana, Heezen, Kim C., Wouters, Roxane A., Verhoef, Cornelis, Verjans, Georges M.G.M., Langerak, Anton W., Grünhagen, Dirk J., Mooyaart, Antien L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245556/ https://www.ncbi.nlm.nih.gov/pubmed/35446267 http://dx.doi.org/10.1097/CMR.0000000000000824 |
Ejemplares similares
-
False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T‐VEC)
por: Mulder, Evalyn E. A. P., et al.
Publicado: (2021) -
Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec
por: Blackmon, Jonathan T., et al.
Publicado: (2017) -
Talimogene laherparepvec: First in class oncolytic virotherapy
por: Conry, Robert M., et al.
Publicado: (2018) -
Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec
por: McClure, Erin M., et al.
Publicado: (2022) -
Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy
por: Rizzo, Jason M., et al.
Publicado: (2018)